Predictive value of early weight loss in obesity management with orlistat: An evidence-based assessment of prescribing guidelines

International Journal of Obesity

Volumn 27, Issue 1, 2003, Pages 103-109

  Rissanen, A ^a,f   Lean, M ^b   Rossner S ^c   Segal, K R ^d   Sjostrom L ^e  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d HOFFMANN LA ROCHE INC   (United States)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f BIOMEDICUM HELSINKI   (Finland)

Author keywords

Orlistat; Retrospective analysis; Risk factors; Weight loss

Indexed keywords

CHOLESTEROL; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET; EVIDENCE BASED MEDICINE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; OBESITY; PRACTICE GUIDELINE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 0037261362     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802165     Document Type: Article

References (22)

1. Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther 1996; 18: 1006-1035.
2. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 6: 397-415.
3. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight U.S. white women age 40-64 years. Am J Epidemiol 1995; 141: 1128-1141.
4. Kramer FM, Jeffery RW, Forster JL, Snell MK. Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women. Int J Obes 1989; 13: 123-136.
5. Wadden TA. Treatment of obesity by moderate and severe calorie restriction: results of clinical research trials. Arch Intern Med 1993; 119: 688-693.
6. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996; 276: 1907-1915.
7. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocrine Reviews 1999; 20: 805-875.
8. Scheen AJ, Lefebvre PJ. Pharmacological treatment of obesity: present status. Int J Obes Relat Metab Disord 1999; 23(Suppl 1): 47-53.
9. Astrup A, Rössner S. Lessons from obesity management programmes: greater initial weight loss improves long-term maintenance. Obes Rev 2000; 1: 17-19.
10. Guy-Grand B, Apfelbaum MN, Crepaldi G, Gries A, Lefebvre P, Turner P. International trial of dexfenfluramine in obesity. Lancet 1989; ii: 1142-1145.
11. Weintraub M, Sundaresan PR, Madan M, Schuster B, Balder A, Lasagna L, Cox C. Long-term weight control study I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 1992; 51: 586-594.
12. National Institutes of Health. National Heart, Lung and Blood Institute. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. National Institutes of Health: Bethesda, MD; 1998.
13. Royal College of Physicians. Clinical management of overweight and obese patients: with particular reference to the use of drugs. Royal College of Physicians: London; 1998.
14. National Institute for Clinical Excellence. Orlistat for the treatment of obesity in adults, 2001, Available from: http://www.nice.org.uk/pdf/orlistatguidance.pdf
15. Sjöström L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-173.
16. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999; 281: 235-242.
17. Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000; 8: 49-61.
18. European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products European Public Assessment Report (EPAR): Xenical. EMEA: London; 1998. Available from: http://www.eudra.org/humandocs/humans/epar/xenical/xenical.htm
19. Lean MEJ. Is long-term weight loss possible?. Br J Nutr 2000; 83(Suppl 1): S103-S111.
20. Winer BJ. Statistical principles in experimental design, 2nd edn. McGraw-Hill: New York; 1971.
21. Sandage BWJ, Loaf SB, Cary M, Cooper GL. Predictors of therapeutic success with dexfenfluramine. Obes Res 1995; 3: 355S. Available from: http://www.fda.gov/ohrms/dockets/ac/95/3107tla.pdf
22. James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, Saris WHM, Van Gaal LF. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000; 356: 2119-2125.